Vertaling van "cancer and hormone-replacement " (Nederlands → Frans) :

Breast cancer and hormone-replacement therapy in the million Women Study.
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

L. Holmberg en H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped.
L. Holmberg et H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?); a randomised comparison: trial stopped.

D. Cook: Shouldn’t adults with growth hormone deficiency be offered growth hormone replacement therapy?
D. Cook: Shouldn’t adults with growth hormone deficiency be offered growth hormone replacement therapy ?

Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Rossouw J, Prentice R, Manson J et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

JAMA 2005; 293:330-9 Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.
JAMA 2005; 293:330-9. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.

Lancet 363, 453-455 (2004) R.T. Chlebowski en N. Col (Commentary): Menopausal hormone therapy after breast cancer.
Lancet 363, 453-455 (2004) R.T. Chlebowski et N. Col (Commentary): Menopausal hormone therapy after breast cancer.

Breast cancer and hormonal contraceptives: collaborative reanalysis of
Breast cancer and hormonal contraceptives:

(Lyytinen 2010) Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. A case-control study on hormone therapy as a risk factor for breast cancer in
(Lyytinen 2010) Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. A case-control study on hormone therapy as a risk factor for breast